Annual Report · 10-K
DYNAVAX TECHNOLOGIES CORP
Annual Report
Company context
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Dynavax has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant. For more information about Dynavax’s marketed products and development pipeline, visit www.dynavax.com.
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗